Suppression of Cancer Growth by Nonviral Gene Therapy Based on a Novel Reactive Oxygen Species-responsive Promoter

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2009 May 14

PMID 19436270

Citations 6

Authors

Lucia L Policastro

Irene L Ibanez

Hebe A Duran

Gaston Soria

Vanesa Gottifredi

Osvaldo L Podhajcer

Affiliations

Soon will be listed here.

Abstract

Increased reactive oxygen species (ROS) production has been reported as a distinctive feature of different pathologies including cancer. Therefore, we assessed whether increased ROS production in the cancer microenvironment could be selectively exploited to develop a selective anticancer therapy. For this purpose, we constructed a novel chimeric promoter, based on a ROS-response motif located in the VEGF gene promoter placed, in turn, downstream of a second ROS-response motif obtained from the early growth response 1 (Egr-1) gene promoter. The activity of the chimeric promoter was largely dependent on variations in intracellular ROS levels and showed a high inducible response to exogenous H(2)O(2). Transient expression of the thymidine kinase (TK) gene driven by the chimeric promoter, followed by gancyclovir (GCV) administration, inhibited human colorectal cancer and melanoma cell growth in vitro and in vivo. Moreover, electrotransfer of the TK gene followed by GCV administration exerted a potent therapeutic effect on established tumors. This response was improved when combined with chemotherapeutic drugs. Thus, we show for the first time that a distinctive pro-oxidant state can be used to develop new selective gene therapeutics for cancer.

Citing Articles

Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.

Yoon A, Hong J, Kim M, Yun C Sci Rep. 2018; 8(1):2233.

PMID: 29396500 PMC: 5797125. DOI: 10.1038/s41598-018-20268-6.

STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.

Kuo W, Hwu L, Wu C, Lee J, Chang C, Liu R Theranostics. 2017; 7(3):647-663.

PMID: 28255357 PMC: 5327640. DOI: 10.7150/thno.16827.

Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Upregulation of antioxidant genes correlates with regression of melanoma malignancy and with malignant progression when downregulated.

Bracalente C, Ibanez I, Berenstein A, Notcovich C, Cerda M, Klamt F Oncotarget. 2016; 7(27):41154-41171.

PMID: 27206673 PMC: 5173049. DOI: 10.18632/oncotarget.9273.

Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Reversion or promotion of malignancy by inducing melanogenesis or metastasis.

Bracalente C, Salguero N, Notcovich C, Muller C, da Motta L, Klamt F Oncotarget. 2016; 7(27):41142-41153.

PMID: 27206672 PMC: 5173048. DOI: 10.18632/oncotarget.9220.

Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.

Bravo S, Nunez F, Cruzat F, Cafferata E, De Ferrari G, Montecino M Mol Ther. 2013; 21(7):1403-12.

PMID: 23712038 PMC: 3702098. DOI: 10.1038/mt.2013.93.

References

Arnold R, Shi J, Murad E, Whalen A, Sun C, Polavarapu R . Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A. 2001; 98(10):5550-5. PMC: 33250. DOI: 10.1073/pnas.101505898. View

Irani K, Xia Y, Zweier J, Sollott S, Der C, Fearon E . Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997; 275(5306):1649-52. DOI: 10.1126/science.275.5306.1649. View

Byrne C, Thompson J, Johnston H, Hersey P, Quinn M, Hughes T . Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005; 15(1):45-51. DOI: 10.1097/00008390-200502000-00008. View

Radisky D, Levy D, Littlepage L, Liu H, Nelson C, Fata J . Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436(7047):123-7. PMC: 2784913. DOI: 10.1038/nature03688. View

Eriksson J . Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett. 2007; 581(19):3734-42. DOI: 10.1016/j.febslet.2007.06.044. View

Modlich U, Pugh C, Bicknell R . Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 2000; 7(10):896-902. DOI: 10.1038/sj.gt.3301177. View

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L . Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56(2):185-229. DOI: 10.1124/pr.56.2.6. View

Halliwell B . Oxidative stress and cancer: have we moved forward?. Biochem J. 2006; 401(1):1-11. DOI: 10.1042/BJ20061131. View

Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke M . Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 2001; 8(4):298-307. DOI: 10.1038/sj.cgt.7700304. View

10.

Ko D, Hawkins L, Yu D . Development of transcriptionally regulated oncolytic adenoviruses. Oncogene. 2005; 24(52):7763-74. DOI: 10.1038/sj.onc.1209048. View

11.

Datta R, Taneja N, Sukhatme V, Qureshi S, Weichselbaum R, Kufe D . Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A. 1993; 90(6):2419-22. PMC: 46098. DOI: 10.1073/pnas.90.6.2419. View

12.

Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A . Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005; 65(3):948-56. View

13.

Marples B, Scott S, Hendry J, Embleton M, Lashford L, Margison G . Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 2000; 7(6):511-7. DOI: 10.1038/sj.gt.3301116. View

14.

Firestein G, Echeverri F, Yeo M, Zvaifler N, Green D . Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A. 1997; 94(20):10895-900. PMC: 23522. DOI: 10.1073/pnas.94.20.10895. View

15.

Li S, Zhang X, Xia X . Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst. 2002; 94(10):762-8. DOI: 10.1093/jnci/94.10.762. View

16.

Veal E, Day A, Morgan B . Hydrogen peroxide sensing and signaling. Mol Cell. 2007; 26(1):1-14. DOI: 10.1016/j.molcel.2007.03.016. View

17.

Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer O, Costa C . Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog. 2004; 39(2):103-13. DOI: 10.1002/mc.20001. View

18.

Romero J, Reckelhoff J . State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999; 34(4 Pt 2):943-9. DOI: 10.1161/01.hyp.34.4.943. View

19.

Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M . Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 2001; 61(7):3016-21. View

20.

Scott S, Joiner M, Marples B . Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther. 2002; 9(20):1396-402. DOI: 10.1038/sj.gt.3301822. View